Earnings Releases·Nov 2, 2026, 4:07 PM ET

Jazz Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total revenues rose 10% YoY to $1.243 billion in Q3 2026, driven by strong performance from Zepzelca (+32% YoY) and Xywav (+12% YoY), while GAAP net loss widened to $483.4 million due to a $754.2 million IPR&D charge from the Actio acquisition.
Full-year 2026 total revenue guidance was raised to $4.775–$4.85 billion, and the company completed a $1.25 billion private placement of exchangeable senior notes while exhausting its previous share repurchase program.
Management approved a new indefinite share repurchase program authorizing up to $500 million and amended its Term Loan B to reduce margins by 50 basis points and extend maturity to May 2033.
Strategic momentum continues with Ziihera sales reaching $21 million post-launch and inclusion in NCCN guidelines as a preferred regimen, alongside the completion of the Actio acquisition to expand the rare epilepsy portfolio.